Navigation Links
Aoxing Pharmaceutical Company Announces Special Funding From Hebei Province in China
Date:11/3/2011

JERSEY CITY, N.J., Nov. 3, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has received a special funding of 2 million RMB (approximately $315,000) from the Industry and Information Technology Department and the Finance Department of Hebei Province in China.  The grant was for manufacturing facility improvements in the form of interest payment assistance on the Company's existing bank loans.

Zhenjiang Yue, Aoxing Pharma's Chairman and CEO, commented, "We appreciate the continued support from our local government here in China."  

About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, and Phoenix PharmaLabs, Inc.  For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. The Company may also make written or oral forward-looking statements in its periodic reports filed with the U.S. Securities and Exchange Commission and other written materials and in oral statements made by its officers, directors or employees to third parties. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2011, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

CONTACT:  

Aoxing Pharmaceutical Company:
Bob Ai
Chief Financial Officer
646-367-1767
investor.relations@aoxingpharma.com

Investor Relations:
The Trout Group
Brian Korb
646-378-2923
bkorb@troutgroup.com


'/>"/>
SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aoxing Pharmaceutical Company Has No Comment on Unusual Trading Activity
2. Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film
3. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
4. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
5. Raging Capital Sends Letter to Taro Pharmaceutical Board of Directors in Opposition to Inadequate Acquisition Offer by Sun Pharmaceutical
6. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Carol Wells Elected President of the Society of Pharmaceutical and Biotech Trainers
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
10. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 TapImmune, ... specializing in the development of innovative peptide and ... metastatic disease, today announced that it will participate ... Dr. Glynn Wilson , Chairman and ... the company,s business, clinical pipeline and partnering opportunities ...
(Date:3/22/2017)... 22, 2017 Piramal Pharma Solutions ... held a special event to introduce the new and ... Lexington, Kentucky . The inaugural event was attended ... Ajay Piramal, and Piramal Pharma Solutions CEO, ... ...
(Date:3/22/2017)... ROCHESTER, N.Y. , March 22, 2017 /PRNewswire/ ... Steriliz R-D™ Rapid Disinfector™ is the proven ultraviolet-C ... that cause healthcare-associated infections (HAIs). ... American Journal of Infection Control , the peer-reviewed ... testing and experiences of Vancouver General Hospital and ...
Breaking Medicine Technology:
(Date:3/23/2017)... DC (PRWEB) , ... March 23, 2017 , ... News ... Dental Choice has helped score a major victory in Europe for public health and ... , Based on rigorous scientific research and the overwhelming support of European ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, an ... issue of its companion print magazine. The new magazine, scheduled for release in ... information provided by board-certified doctors from across the country. , According to the ...
(Date:3/22/2017)... ... ... Old School Labs™, makers of the best-selling Vintage line of natural sports ... who trained with Floyd Mayweather, made his professional debut in London in 2003 and ... number of wins in contests in Britain, Germany and the U.S. , “We ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... today announced that its digital marketing solutions have enabled Children’s Hospital of The ... 24 months. , Recognizing the value of a digital marketing approach, the ...
Breaking Medicine News(10 mins):